Study Details

Back
Study ID CDP870-275-11-001/1226-CL-B001
Study Title A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-groupStudy to Assess the Efficacy and Safety of CDP870 in Patients with Early-stage Rheumatoid Arthritis Who Are Naïve to Methotrexate and Have Poor Prognostic Factors (Plain Language Summary in Japanese.)
Clinicaltrials.gov Identifier NCT01451203
Compound Name CDP870 / certolizumab pegol
Medical Indication or Disease Rheumatoid arthritis
Study Sponsor Astellas Pharma Inc.
Collaborator UCB Japan Co. Ltd.
Study Start Date 11-Oct-2011
Study Completion Date 20-Oct-2014
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
Japanese

QUICK SEARCH

USEFUL LINKS